Evommune (EVMN) Q1 2026 earnings summary

Executive summary

• Focused on developing therapies for chronic inflammatory diseases, with lead candidates EVO756 and EVO301 in Phase 2 development targeting CSU, AD, migraine, and UC.

• Enrollment completed for Phase 2b trials of EVO756 in CSU and AD, with top-line data expected in June and Q3 2026, respectively.

• Positive Phase 2a proof-of-concept data for EVO301 in AD; subcutaneous formulation work completed and Phase 2b trial planned for mid-2027.

• Plans to initiate Phase 2b trial of EVO756 in migraine prophylaxis in mid-2026, with top-line data anticipated in 2027.

• No product revenue yet; operations funded by equity and license revenue, with a $242.8 million accumulated deficit as of March 31, 2026.

Financial highlights

• Cash, cash equivalents, and investments totaled $307.0 million as of March 31, 2026, up from $216.7 million at December 31, 2025.

• No revenue recognized in Q1 2026; Q1 2025 included $3.0 million in non-recurring license revenue.

• Research and development expenses rose 21% year-over-year to $17.3 million, driven by clinical trials and discovery research.

• General and administrative expenses increased 81% year-over-year to $6.6 million, mainly due to higher stock-based compensation and public company costs.

• Net loss for Q1 2026 was $21.7 million, compared to $14.6 million in Q1 2025.

Outlook and guidance

• Cash runway expected to fund operations through 2028 based on current business plan.

• Top-line Phase 2b data for EVO756 in CSU expected in June 2026 and in AD in Q3 2026.

• Phase 2b trial for EVO756 in migraine prophylaxis to begin mid-2026, with data expected in 2027.

• Phase 2b trial for subcutaneous EVO301 in AD planned for mid-2027.

• Additional funding will be required for further development and commercialization efforts.